PDF herunterladen
CC BY 4.0 · World J Nucl Med 2023; 22(02): 087-099
DOI: 10.1055/s-0043-1764307
Review Article

Assessment of Pulmonary Metastasis in Differentiated Thyroid Carcinoma: Value of HRCT Correlation with Functional Imaging

Ashwini Kalshetty 
1   Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Parel, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sandip Basu 
1   Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Parel, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Pulmonary metastases in thyroid carcinoma demonstrates varying imaging characteristics and disease biology and the outcome. The valuable complimentary role of high-resolution CT (HRCT) in conjunction with functional imaging such as radioiodine scan has been discussed and illustrated in this review along with the varied clinical and imaging presentations of lung metastases from differentiated thyroid cancer (DTC). A multi-modality patient-specific diagnostic approach and awareness about the atypical presentations helps in early identification as well as effective management of these patients, and especially in certain situations that could need multi-disciplinary management. While HRCT of the lungs as an added tool provides detailed visualization of the lung parenchyma, in the era of hybrid imaging, the routine adoption of SPECT-CT in patients with pulmonary metastases (in diagnostic or post-treatment settings) could provide equivalent or even incremental information from further management viewpoint.

Keywords

differentiated thyroid carcinoma - pulmonary metastasis - high resolution CT (HRCT) - multiple detector computed tomography (MDCT) - radioiodine scintigraphy - chest X-ray - SPECT-CT


Publikationsverlauf

Artikel online veröffentlicht:
28. April 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
    Suche in Google Scholar
  • 2 Cho SW, Choi HS, Yeom GJ. et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid 2014; 24 (02) 277-286
    CrossrefPubMedSuche in Google Scholar
  • 3 Wu S, Wang H. Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer. Ann Endocrinol (Paris) 2013; 74 (01) 40-44
    CrossrefPubMedSuche in Google Scholar
  • 4 Nakagawa T. [CT of metastatic pulmonary tumor: morphology, HRCT and histological correlation]. Nippon Igaku Hoshasen Gakkai Zasshi 1996; 56 (14) 1032-1038
    PubMedSuche in Google Scholar
  • 5 Kuo SF, Chen ST, Kao PF, Chang YC, Chou SC, Lin JD. Papillary thyroid cancer with chest metastases only detected using radioactive iodine. Chang Gung Med J 2004; 27 (09) 663-672
    PubMedSuche in Google Scholar
  • 6 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (08) 2892-2899
    CrossrefPubMedSuche in Google Scholar
  • 7 Robbins RJ, Wan Q, Grewal RK. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (02) 498-505
    CrossrefPubMedSuche in Google Scholar
  • 8 Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S. Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer?. Thyroid 2004; 14 (03) 217-225
    CrossrefPubMedSuche in Google Scholar
  • 9 Jang S, Chung J-K, Kang KW, Lee DS, Lee MC. Assessment of pulmonary uptake in post-therapy I-131 whole body scan in well differentiated thyroid cancer patients. J Nucl Med 2009; 50 (Suppl. 02) 389
    Suche in Google Scholar
  • 10 Basu S, Kalshetty A. Volumetric high-resolution computed tomography in evaluating pulmonary metastases from differentiated thyroid carcinoma: considerations for evolving the optimal diagnostic pathway. Nucl Med Commun 2017; 38 (10) 881-882
    CrossrefPubMedSuche in Google Scholar
  • 11 Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging 2012; 2 (03) 362-385
    PubMedSuche in Google Scholar
  • 12 Chung JK, So Y, Lee JS. et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40 (06) 986-992
    PubMedSuche in Google Scholar
  • 13 Choi SJ, Jung KP, Lee SS, Park YS, Lee SM, Bae SK. Clinical usefulness of F-18 FDG PET/CT in papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody. Nucl Med Mol Imaging 2016; 50 (02) 130-136
    CrossrefPubMedSuche in Google Scholar
  • 14 Qiu ZL, Wei WJ, Shen CT. et al. Diagnostic performance of 18F-FDG PET/CT in papillary thyroid carcinoma with negative 131I-WBS at first postablation, negative Tg and progressively increased TgAb level. Sci Rep 2017; 7 (01) 2849
    CrossrefPubMedSuche in Google Scholar
  • 15 Bakheet SM, Powe JE, Hammami MM, Ahmed M. Comparison of F-18 FDG to I-123 and I-131 scans in thyroid carcinoma. Clin Nucl Med 1997; 22 (06) 438-439
    CrossrefPubMedSuche in Google Scholar
  • 16 Hassan FU, Mohan HK. Clinical utility of SPECT/CT imaging post-radioiodine therapy: does it enhance patient management in thyroid cancer? [Internet]. Eur Thyroid J 2015; 4 (04) 239-245
    CrossrefPubMedSuche in Google Scholar
  • 17 Wang R, Zhang Y, Tan J. et al. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Medicine (Baltimore) 2017; 96 (19) e6809
    CrossrefPubMedSuche in Google Scholar
  • 18 Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol 2015; 173 (03) 399-408
    CrossrefPubMedSuche in Google Scholar
  • 19 Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer 2017; 123 (15) 2955-2964
    CrossrefPubMedSuche in Google Scholar
  • 20 Sabra MM, Sherman E, Tuttle RM. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy. Clin Endocrinol (Oxf) 2019; 90 (04) 617-622
    CrossrefPubMedSuche in Google Scholar
  • 21 Chen P, Feng H-J, Ouyang W. et al. Risk factors for nonremission and progression free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer:A single institute, retrospective analysis in Southern China. Endocr Pract 2016; 22 (09) 1048-1056
    CrossrefPubMedSuche in Google Scholar
  • 22 Sohn SY, Kim HI, Kim YN, Kim TH, Kim SW, Chung JH. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clin Endocrinol (Oxf) 2018; 88 (02) 318-326
    CrossrefPubMedSuche in Google Scholar
  • 23 Chopra S, Garg A, Ballal S, Bal CS. Lung metastases from differentiated thyroid carcinoma: prognostic factors related to remission and disease-free survival. Clin Endocrinol (Oxf) 2015; 82 (03) 445-452
    CrossrefPubMedSuche in Google Scholar
  • 24 Wang H, Dai H, Li Q, Shen G, Shi L, Tian R. Investigating 18F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol 2021; 11: 648658 . PMID: 34055616; PMCID: PMC8158293
    CrossrefPubMedSuche in Google Scholar
  • 25 Basu S, Kalshetty A. Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?. Eur J Nucl Med Mol Imaging 2017; 44 (06) 1092-1094
    CrossrefPubMedSuche in Google Scholar
  • 26 Ranade R, Kand P, Basu S. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome). Nucl Med Commun 2015; 36 (10) 1014-1020
    CrossrefPubMedSuche in Google Scholar